ICON Plc Released The Findings Of A Survey Of Over 120 Biotech And Pharma Professionals Developing Treatments For Neurodegenerative Disorders
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer's and Related Disorders ICON Survey
ICON Plc Draws Bullish Views at RBC on Attractive Valuation
Icon Shares Are Trading Higher After RBC Capital Initiated Coverage on the Stock With an Outperform Rating and Announced a Price Target of $263.
ICON Up Over 5%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday